Background
Methods
Population and data
Immune-mediated diseases (ICD-10 codes) | England, 1999 – 2011 | |
---|---|---|
N | % of females | |
Addison’s disease (E27) | 11 839 | 59 |
Ankylosing spondylitis (M45) | 29 136 | 30 |
Autoimmune haemolytic anaemia (D59.1) | 9 241 | 54 |
Chronic active hepatitis (K73.2) | 4 439 | 70 |
Coeliac disease (K90) | 70 715 | 67 |
Crohn’s disease (K50) | 125 240 | 56 |
Dermatomyositis (M33.0-M33.1) | 2 768 | 67 |
Diabetes mellitus (E10) | 426 471 | 46 |
Goodpasture’s syndrome (M31) | 1 058 | 49 |
Hashimoto’s thyroiditis (E06.3) | 8 630 | 90 |
Idiopathic thrombocytopenia purpura (D69) | 31 043 | 55 |
Multiple sclerosis (G35) | 82 256 | 69 |
Myasthenia gravis (G70) | 11 279 | 49 |
Myxoedema (E03.8–E03.9) | 938 696 | 81 |
Pemphigoid (L12) | 13 642 | 56 |
Pemphigus (L10) | 2 348 | 56 |
Pernicious anaemia (D51.0) | 67 890 | 68 |
Polyarteritis nodosa (M30.0) | 2 249 | 44 |
Polymyositis (M33.2) | 3 860 | 62 |
Primary biliary cirrhosis (K74) | 11 146 | 84 |
Psoriasis (L40) | 119 454 | 48 |
Rheumatoid arthritis (M05–M06) | 331 393 | 71 |
Scleroderma (M34) | 11 494 | 82 |
Sjogren’s syndrome (M35.0) | 17 741 | 89 |
Systemic lupus erythematosus (M32) | 25 576 | 86 |
Thyrotoxicosis (E05) | 132 826 | 79 |
Ulcerative colitis (K51) | 180 397 | 49 |
Statistical methods
Results
Immune mediated disease | Observed | Rate ratio (95% CI) | P value |
---|---|---|---|
Addison’s disease
|
25
|
2.01 (1.3-2.97)
|
0.001*
|
Ankylosing spondylitis
|
46
|
1.64 (1.2-2.19)
|
0.001*
|
Autoimmune haemolytic anaemia
|
16
|
1.99 (1.14-3.23)
|
0.009
|
Chronic active hepatitis | 1 | 0.18 (0-0.99) | 0.08 |
Coeliac disease | 72 | 1.04 (0.82-1.32) | 0.76 |
Crohn’s disease
|
159
|
1.29 (1.1-1.51)
|
0.001*
|
Dermatomyositis | 3 | 1.27 (0.26-3.7) | 0.93 |
Diabetes mellitus
|
534
|
1.21 (1.11-1.33)
|
<0.001*
|
Goodpasture’s syndrome | 2 | 2.31 (0.28-8.34) | 0.50 |
Hashimoto’s thyroiditis | 10 | 0.97 (0.46-1.78) | 0.96 |
Idiopathic thrombocytopenia purpura
|
62
|
2.42 (1.86-3.11)
|
<0.001*
|
Multiple sclerosis | 115 | 1.09 (0.9-1.31) | 0.41 |
Myasthenia gravis | 12 | 0.93 (0.48-1.62) | 0.91 |
Myxoedema
|
1283
|
1.15 (1.09-1.22)
|
<0.001*
|
Pemphigoid | 16 | 1.29 (0.74-2.1) | 0.38 |
Pemphigus | 3 | 1.35 (0.28-3.94) | 0.85 |
Pernicious anaemia
|
96
|
1.3 (1.05-1.59)
|
0.013
|
Polyarteritis nodosa | 4 | 1.79 (0.49-4.6) | 0.40 |
Polymyositis | 8 | 1.81 (0.78-3.56) | 0.15 |
Primary biliary cirrhosis
|
30
|
2.21 (1.49-3.16)
|
<0.001*
|
Psoriasis
|
156
|
1.34 (1.14-1.57)
|
<0.001*
|
Rheumatoid arthritis
|
640
|
1.48 (1.36-1.6)
|
<0.001*
|
Scleroderma
|
25
|
1.84 (1.19-2.72)
|
0.003
|
Sjogren’s syndrome
|
39
|
1.69 (1.2-2.31)
|
0.001*
|
Systematic lupus erythematosus
|
108
|
3.76 (3.08-4.55)
|
<0.001*
|
Thyrotoxicosis
|
202
|
1.38 (1.19-1.58)
|
<0.001*
|
Ulcerative colitis | 198 | 1.00 (0.87-1.16) | 0.99 |
Immune mediated disease | Observed | Rate ratio (95% CI) | P value |
---|---|---|---|
Addison’s disease
|
7
|
2.77 (1.11-5.73)
|
0.01
|
Ankylosing spondylitis
|
12
|
1.99 (1.02-3.49)
|
0.03
|
Autoimmune haemolytic anaemia | 5 | 2.33 (0.75-5.44) | 0.11 |
Chronic active hepatitis | 0 | 0 (0-3.75) | 0.63 |
Coeliac disease
|
23
|
1.62 (1.03-2.45)
|
0.03
|
Crohn’s disease | 26 | 1.16 (0.75-1.71) | 0.52 |
Dermatomyositis | 1 | 1.75 (0.04-9.77) | 0.93 |
Diabetes mellitus
|
144
|
1.68 (1.40-2.00)
|
<0.001*
|
Goodpasture’s syndrome | 0 | 0 (0-16.34) | 0.56 |
Hashimoto’s thyroiditis | 2 | 0.95 (0.11-3.42) | 0.79 |
Idiopathic thrombocytopenia purpura
|
22
|
3.72 (2.32-5.66)
|
<0.001*
|
Multiple sclerosis | 28 | 1.47 (0.97-2.14) | 0.06 |
Myasthenia gravis | 4 | 1.44 (0.39-3.71) | 0.66 |
Myxoedema
|
460
|
1.54 (1.38-1.72)
|
<0.001*
|
Pemphigoid | 7 | 1.91 (0.77-3.94) | 0.14 |
Pemphigus | 1 | 1.75 (0.04-9.77) | 0.92 |
Pernicious anaemia
|
30
|
1.5 (1.01-2.15)
|
0.04
|
Polyarteritis nodosa | 2 | 4.11 (0.5-14.88) | 0.15 |
Polymyositis | 2 | 2.12 (0.26-7.67) | 0.57 |
Primary biliary cirrhosis
|
11
|
3.32 (1.65-5.96)
|
<0.001*
|
Psoriasis | 34 | 1.31 (0.9-1.84) | 0.15 |
Rheumatoid arthritis
|
157
|
1.63 (1.37-1.93)
|
<0.001*
|
Scleroderma | 6 | 1.9 (0.69-4.14) | 0.19 |
Sjogren’s syndrome | 5 | 0.89 (0.29-2.08) | 0.96 |
Systematic lupus erythematosus
|
28
|
4.78 (3.16-6.95)
|
<0.001*
|
Thyrotoxicosis
|
49
|
1.38 (1.02-1.84)
|
0.03
|
Ulcerative colitis | 31 | 0.87 (0.59-1.24) | 0.49 |
Immune mediated disease | Observed | Rate ratio (95% CI) | P value |
---|---|---|---|
Addison’s disease
|
18
|
1.82 (1.08-2.88)
|
0.02
|
Ankylosing spondylitis
|
34
|
1.55 (1.07-2.16)
|
0.01
|
Autoimmune haemolytic anaemia | 11 | 1.87 (0.93-3.34) | 0.06 |
Chronic active hepatitis | 1 | 0.21 (0.01-1.2) | 0.14 |
Coeliac disease | 49 | 0.89 (0.66-1.18) | 0.48 |
Crohn’s disease
|
133
|
1.32 (1.11-1.57)
|
0.002
|
Dermatomyositis | 2 | 1.11 (0.13-4.02) | 0.83 |
Diabetes mellitus | 390 | 1.10 (0.99-1.22) | 0.067 |
Goodpasture’s syndrome | 2 | 3.12 (0.38-11.27) | 0.28 |
Hashimoto’s thyroiditis | 8 | 0.97 (0.42-1.91) | 0.93 |
Idiopathic thrombocytopenia purpura
|
40
|
2.04 (1.45-2.78)
|
<0.001*
|
Multiple sclerosis | 87 | 1 (0.8-1.24) | 0.97 |
Myasthenia gravis | 8 | 0.79 (0.34-1.55) | 0.61 |
Myxoedema | 823 | 1.02 (0.95-1.1) | 0.53 |
Pemphigoid | 9 | 1.03 (0.47-1.96) | 0.94 |
Pemphigus | 2 | 1.21 (0.15-4.37) | 0.91 |
Pernicious anaemia | 66 | 1.22 (0.95-1.56) | 0.12 |
Polyarteritis nodosa | 2 | 1.15 (0.14-4.15) | 0.85 |
Polymyositis | 6 | 1.72 (0.63-3.75) | 0.28 |
Primary biliary cirrhosis
|
19
|
1.86 (1.12-2.9)
|
0.01
|
Psoriasis
|
122
|
1.35 (1.12-1.62)
|
0.001*
|
Rheumatoid arthritis
|
483
|
1.44 (1.31-1.58)
|
<0.001*
|
Scleroderma
|
19
|
1.83 (1.1-2.85)
|
0.012
|
Sjogren’s syndrome
|
34
|
1.94 (1.35-2.72)
|
<0.001*
|
Systematic lupus erythematosus
|
80
|
3.5 (2.77-4.36)
|
<0.001*
|
Thyrotoxicosis
|
153
|
1.38 (1.16-1.62)
|
<0.001*
|
Ulcerative colitis | 167 | 1.03 (0.88-1.2) | 0.71 |